Journal of Clinical and Cellular Immunology
Open Access
ISSN: 2155-9899
ISSN: 2155-9899
Jos M.H. Raats
ModiQuest B.V., Pivot Park-LSC,
Molenweg 79, 5349 AC Oss
England
Research Article
Anti-Citrullinated Protein Antibodies as Novel Therapeutic Drugs in Rheumatoid Arthritis
Author(s): Renato G.S. Chirivi, Guido J. Jenniskens, and Jos M.H. RaatsRenato G.S. Chirivi, Guido J. Jenniskens, and Jos M.H. Raats
We have developed a novel antibody-based treatment for rheumatoid arthritis. In a collagen antibody-induced arthritis mouse model, anti-citrullinated protein antibodies (ACPAs) prevent the onset and/or exacerbation of inflammation, and prevent or strongly reduce joint damage. For the development of this novel therapy, we focussed on rheumatoid arthritis-specific citrullinated peptide epitopes. A growing number of studies indicate that modifications of arginines into citrulline residues are responsible for the initial triggering of autoimmunity and the breaking of tolerance. We identified a subset of human recombinant ACPAs that prevent the onset of inflammation in both collagen-induced arthritis and collagen antibody-induced arthritis mouse models for rheumatoid arthritis. Therapeutic administration of these antibodies resulted in the arrest of the inflammation and prevented a further.. View More»
DOI:
10.4172/2155-9899.S6-006